💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Voclosporin

CHEMBL5314379 Phase 4 承認済み Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
1214.6 g/mol
LogP
7.9
Phase
4

Voclosporin is a novel calcineurin inhibitor structurally related to cyclosporine that suppresses T-cell activation by blocking calcineurin-mediated dephosphorylation of NFAT transcription factors, thereby reducing IL-2 production and T-cell proliferation in immune-mediated diseases. It is approved for the treatment of adult patients with active lupus nephritis in combination with immunosuppressive background therapy. Compared to cyclosporine, voclosporin has a more predictable pharmacokinetic profile and additional podocyte-stabilizing effects.

分子量

1214.6000 g/mol

LogP

7.90

TPSA

279.00 Ų

リピンスキーの五則

不適合

治療領域

Psoriasis Systemic Lupus Erythematosus

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C=C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C

                

                

                
                

                    
InChI

                    
InChI=1S/C63H111N11O12/c1-25-27-28-29-41(15)53(76)52-57(80)66-44(26-2)59(82)68(18)34-49(75)69(19)45(30-35(3)4)56(79)67-50(39(11)12)62(85)70(20)46(31-36(5)6)55(78)64-42(16)54(77)65-43(17)58(81)71(21)47(32-37(7)8)60(83)72(22)48(33-38(9)10)61(84)73(23)51(40(13)14)63(86)74(52)24/h25,27-28,35-48,50-53,76H,1,26,29-34H2,2-24H3,(H,64,78)(H,65,77)(H,66,80)(H,67,79)/b28-27+/t41-,42+,43-,44+,45+,46+,47+,48+,50+,51+,52+,53-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C63H111N11O12

                    

                    
                    

                        
HBD / HBA

                        
5 / 12

                    

                    
                    

                        
回転可能結合数

                        
16

                    

                    
                    
                    

                        
重原子数

                        
86

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
Voclosporin is a novel calcineurin inhibitor structurally related to cyclosporine that suppresses T-cell activation by blocking calcineurin-mediated dephosphorylation of NFAT transcription factors, thereby reducing IL-2 production and T-cell proliferation in immune-mediated diseases. It is approved for the treatment of adult patients with active lupus nephritis in combination with immunosuppressive background therapy. Compared to cyclosporine, voclosporin has a more predictable pharmacokinetic profile and additional podocyte-stabilizing effects.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Voclosporin is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL5314379.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 6918486.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.